CoChat

Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations

Thaman, Pragya, Kulig, Caitlin E., Greer, Daniel · 2024 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Purpose/Background: Schizophrenia is a chronic, debilitating mental illness that incurs a large economic burden. Decreasing hospital readmissions is a priority in health care to improve patient quality of life and decrease health care costs. Determining ways to prevent readmissions such as improving access to long-acting injectable (LAI) antipsychotics is important to assess. Methods/Procedures: A single-center retrospective review was conducted comparing readmission rates of patients diagnosed with schizophrenia or schizoaffective disorder discharged on LAI or oral antipsychotics between August 1, 2019, and June 30, 2022. The primary outcome was the 30-day psychiatric readmission rate. Secondary outcomes included chlorpromazine equivalent doses and use of anticholinergic medications. Findings/Results: The 30-day readmission rate was 1.9% for the LAI antipsychotic group and 8.3% for the oral antipsychotic group (P = 0.03; 95% confidence interval, 1.05–20.02). The average chlorpromazine equivalent antipsychotic dose of patients discharged on LAI versus oral antipsychotic medications was 477.3 and 278.6 mg/d, respectively (P < 0.001). In addition, the prevalence of medications used to treat extrapyramidal symptom was 22.3% (n = 23) for the LAI antipsychotic group and 30.8% (n = 74) for the oral antipsychotic group (P = 0.12). Sixty-four percent of LAI antipsychotics utilized were obtained from pharmaceutical company hospital inpatient free trial programs. Implications/Conclusions: Long-acting injectable antipsychotics showed a statistically significant reduction in 30-day rehospitalizations as compared with oral antipsychotics and hospital inpatient free trial programs aided in LAI antipsychotic acquisition.

Overview

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000001810

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. 2022, What are dose conversions from oral to injectable for the long-acting injectable (LAI) antipsychotic medications available in the U.S., SMI Advisor

Cited by

See all 4

Metadata

Authors
Thaman, P., Kulig, C. E., & Greer, D.
Affiliations
Rutgers, The State University of New Jersey (US)
Corresponding author
Greer, Daniel
Venue
Journal of Clinical Psychopharmacology
Published
2024-01-16
Volume
44
Issue
2
Pages
96-99
ISSN
  • 0271-0749 (ISSN-L)
  • 1533-712X
OpenAlex
W4390903411
Cited by
4
References
17
Citations by year
2026: 2 · 2024: 2
FWCI
1.17
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
  • Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
Keywords
long-acting injectable antipsychotics, oral antipsychotics, schizophrenia, schizoaffective disorder, psychiatric rehospitalization, hospital readmission, chlorpromazine equivalents, anticholinergic agents, extrapyramidal symptoms, access to medicines
MeSH terms
Administration, Oral, Chlorpromazine, Delayed-Action Preparations, Humans, Injections, Patient Readmission, Quality of Life, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations. https://app.cochat.ai/papers/10.1097/jcp.0000000000001810
The paper
Thaman, P., Kulig, C. E., & Greer, D. (2024). Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001810

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.